Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1AVCZ)

• Drug Name: N-oleoyl-dopamine Drug Info
• Synonyms: N-Oleoyldopamine; OLDA; N-Oleoyl dopamine; N-oleoyl-dopamine; 105955-11-1; OLEOYL DOPAMINE; UNII-T87P7X9XSZ; T87P7X9XSZ; N-[2-(3,4-dihydroxyphenyl)ethyl]-9Z-octadecenamide; CHEMBL250711; CHEBI:31883; (Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]octadec-9-enamide; SR-01000076132; AC1NQZHH; Lopac-O-2139; Lopac0_001058; SCHEMBL93916; MLS002153451; N-(9Z-octadecanoyl)-dopamine; GTPL5552; BML3-G02; cid_5282106; (9Z)- N-(2-(3,4-Dihydroxyphenyl)ethyl)-9-octadecenamide; MolPort-003-959-070; QQBPLXNESPTPNU-KTKRTIGZSA-N; HMS3648E03; HMS3263C18

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5282106
  ChEBI ID: CHEBI:31883
  CAS Number: CAS 105955-11-1
  TTD Drug ID: DM1AVCZ

Molecule-Related Drug Atlas

Drug(s) Targeting Bacterial Lethal factor (Bact lef)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IQ-DAA	DMHP71R	Bacillus anthracis infection	1G40	Phase 1	[4]
GM6001	DM7V9CT	Corneal ulcer	9A76	Discontinued in Phase 2	[5]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[6]
MMI270	DM38N2K	Discovery agent	N.A.	Investigative	[7]
NSC-622445	DME35CB	Discovery agent	N.A.	Investigative	[8]
N-(Sulfanylacetyl)Tyrosylprolylmethioninamide	DMWJDYZ	Discovery agent	N.A.	Investigative	[5]
N-(3,4-dihydroxybenzyl)oleamide	DM67XSW	Discovery agent	N.A.	Investigative	[9]
N,N'-Bis(4-Amino-2-Methylquinolin-6-Yl)Urea	DMT4USP	Discovery agent	N.A.	Investigative	[5]
N-hydroxy-4-(oleamidomethyl)benzamide	DMUSHZK	Discovery agent	N.A.	Investigative	[9]
N-(3,4,5-trihydroxyphenethyl)oleamide	DMQ5USA	Discovery agent	N.A.	Investigative	[2]

Drug(s) Affected By Transient receptor potential cation channel subfamily V member 1 (TRPV1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[10]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[11]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[12]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[13]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[14]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[15]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[16]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[17]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[18]
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Lethal factor (Bact lef)	TTIQSC1	LEF_BACAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Transient receptor potential cation channel subfamily V member 1 (TRPV1)	OTHHDR03	TRPV1_HUMAN	Gene/Protein Processing	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5552).
• [2] Inhibitors of anthrax lethal factor. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4575-8.
• [3] N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem. 2003 Apr 18;278(16):13633-9. doi: 10.1074/jbc.M211231200. Epub 2003 Feb 4.
• [4] Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol.2009 Feb;4(1):35-43.
• [5] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [6] Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob Agents Chemother. 2007 Jul;51(7):2403-11.
• [7] The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8.
• [8] Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. J Med Chem. 2006 Aug 24;49(17):5232-44.
• [9] Inhibitors of anthrax lethal factor based upon N-oleoyldopamine. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2467-70.
• [10] Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001 Oct;134(4):845-52. doi: 10.1038/sj.bjp.0704327.
• [11] Comparison of protective effect of ascorbic acid on redox and endocannabinoid systems interactions in in vitro cultured human skin fibroblasts exposed to UV radiation and hydrogen peroxide. Arch Dermatol Res. 2017 May;309(4):285-303. doi: 10.1007/s00403-017-1729-0. Epub 2017 Mar 11.
• [12] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [13] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [14] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [15] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [16] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [17] The anthelminthic drug praziquantel is a selective agonist of the sensory transient receptor potential melastatin type 8 channel. Toxicol Appl Pharmacol. 2017 Dec 1;336:55-65. doi: 10.1016/j.taap.2017.10.012. Epub 2017 Oct 18.
• [18] Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol. 2004 Mar;13(3):129-39. doi: 10.1111/j.0906-6705.2004.0178.x.
• [19] The vanilloid receptor TRPV1 is activated and sensitized by local anesthetics in rodent sensory neurons. J Clin Invest. 2008 Feb;118(2):763-76. doi: 10.1172/JCI32751.